CAM26 and CAM29 Cytosol Levels in Breast Tumors Classified According to Estrogen Receptor Status. First Results

Magnani J.L. , Linsley P.S. , Brown J.P. , Horn D. . Monoclonal antibody Onc-M26 which detects elevated levels of mucin in sera from breast cancer patients binds a sugar sequence in sialy lated lacto-n-fucopentaose III. IX International Symposium on Glyconjugates. July 6-11. Lille 1987.

Linsley P.S. , Brown J.P. , Magnani J.L. , Horn D.H. . Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast carcinoma patients. Cancer Res 1988; 48: 2138–48.

Bieglmayer C. , Szepesi T. , Kopp B. CA15.3, MCA, CAM26, CAM29 are members of a polymorphic family of mucin-like glycoproteins. Tumor Biol 1991; 12: 138–48.

Dnistrian A.M. , Schwartz M.K. , Greenberg E.J. , Smith C.A. , Schwartz D.C. . Evaluation of CAM26, CAM29, CA15.3 and CEA as circulating tumor markers in breast cancer patients. Tumor Biol 1991; 12: 82–90.

Eskelinen M. , Tikanoja S. , Brown J. . Clinical evaluation of new serum tumor markers CAM26 and CAM29 in patients with primary breast cancer. Anticancer Res 1990; 10: 959–62.

Yedena C. , Van Kamp G. , de Bruijn H. Pretreatment levels of CAM26 and CAM29 mucin tumor markers in patients with carcinomas of different origins: first results with follow-up sera. Tumor Biol 1990; 11: 92.

Ma Fdez Fdez , Suarez B. , González C. , Allende MaT . Estudio de las concentraciones citosólicas de CAM26 y CAM29 en tumores mamarios clasificados en función del estadio clínico. Rev Clin Esp (in press).

Koliyanni A. , Mylonakis B. , Lazaridis I. . Effect of therapy on benign mastopathy in the levels of CA15.3 antigen. I International Congress Senology. Athens 1988.

Vizoso F. , Allende MaT , Diez MaC , Ruibal A. . Evidence of a correlation between CA15.3 and estradiol levels in women with fibrocystic (non macrocysts) mastopathy. Int J Biol Markers 1991; 6: 33–4.

Vizoso F. , Allende MaT , Fueyo A. , Riera L. , López Otin C. , Ruibal A. . Evidence of a correlation between CA15.3 and prolactin serum levels after TRH administration in women with gross cystic breast disease. Int J Biol Markers 1991; 6: 31–2.

Lundy J. , Schuss A. , Stanick D. , Sadri D. . The CA15.3 assay in patients with benign breast disease and operable breast cancer. Proc ASCO, 1988.

Mac Carty K. , Cox C. , Silva J.S. Comparison of sex steroid receptors analyses and carcinoembryonic antigen with clinical response to hormone therapy. Cancer 1980; 46: 2846–50.

Priolo G. , Pecchio F. , Rapellino M. , Aimo G. , Spertino F. , Pepe C. . CAM26 and CAM29: methodological evaluations and first clinical employment in breast cancer. J Nucl Med All Sci 1990; 34(suppl.): 21–3.

Foekens J.A. , Rio M.C. , Seguin P. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 1990; 50: 3832–7.